AI Article Synopsis

  • Maternal RhD alloimmunization is an immune response that occurs when a pregnant woman's body recognizes the protein antigens in fetal red blood cells (RBC) as foreign.
  • This study analyzed inflammatory chemokine levels in 46 pregnant women, distinguishing between 30 non-alloimmunized and 16 previously alloimmunized women, revealing significantly higher CXCL8 levels and lower CXCL9 and CXCL10 levels in the alloimmunized group.
  • The study also identified the RhD status of fetuses, showing that among the alloimmunized mothers, some had anti-D alloantibodies, and further research on serum chemokines and placenta tissue could deepen understanding of the alloim

Article Abstract

Maternal RhD alloimmunization is an inflammatory response against protein antigens in fetal red blood cells (RBC). However, not all women become alloimmunized when exposed to RhD fetal RBC. Thus, this study aimed to evaluate levels of inflammatory chemokines in RhD pregnant women with erythrocyte alloimmunization. CXCL8, CXCL9, CCL5, and CXCL10 levels were determined from cell culture supernatants by flow cytometry in 46 (30 non-alloimmunized RhD and 16 previously alloimmunized RhD) pregnant women. CXCL8 levels were significantly higher ( < 0.004), and CXCL9 ( < 0.008) and CXCL10 ( < 0.003) levels were significantly lower in alloimmunized pregnant women. No significant difference in CCL5 levels was detected between the groups. Fetal RHD genotyping was performed in the alloimmunized RhD group by real-time PCR. Anti-D alloantibody was detected in 10 mothers and anti-D and -C in six mothers. Twelve fetuses were RHD positive and four were RHD negative. Further studies of serum chemokines and placenta tissue could provide a better understanding of the cells involved in the pathogenesis of maternal erythrocyte alloimmunization.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494496PMC
http://dx.doi.org/10.3389/fimmu.2017.00700DOI Listing

Publication Analysis

Top Keywords

maternal rhd
8
rhd alloimmunization
8
rhd pregnant
8
pregnant women
8
rhd
6
high levels
4
levels cxcl8
4
cxcl8 low
4
levels
4
low levels
4

Similar Publications

Serial intrauterine transfusion for severe fetal anemia due to anti-M alloimmunization.

Asian J Transfus Sci

September 2022

Department of Obstetrics and Gynecology, Faculty of Medicine Padjajaran University, Hasan Sadikin General Hospital, Bandung, Indonesia.

Anti-M antibody is one of the causes of severe fetal anemia and intrauterine death despite its relatively low frequency. A G3P2 26-year-old pregnant woman referred to our hospital at 29 weeks gestational age (WGA) with fetal hydrops. Her second pregnancy results in intrauterine fetal death at 35 WGA due to fetal hydrops.

View Article and Find Full Text PDF

Hemolytic disease of foetus and newborn (HDFN) is a disease characterized by the destruction of fetal red cells by the maternal antibodies which occurs due to allo immunization in the mother by feto-maternal blood group incompatibility. The antibodies most frequently implicated in HDFN may vary depending on the demographic location under consideration. In areas where RhIg administration is available, ABO antibodies are more commonly implicated.

View Article and Find Full Text PDF

Background: Rheumatic heart disease (RHD) remains as 1 of the major contributors to indirect pregnancy-related mortality and morbidity worldwide and disproportionately affects marginalized populations.

Objectives: In this scoping review, the authors sought to explore the socioeconomic, cultural, and health care access-related causes of global disparities in outcomes of pregnancy among individuals with RHD.

Methods: We performed a literature search of all studies published between January 1, 1990, and January 1, 2022, that investigated causes for disparate outcomes in pregnant individuals with RHD.

View Article and Find Full Text PDF

The traditional approach to resuscitating injured women of childbearing potential (WCBP) with an unknown RhD type is to transfuse RhD-negative blood products. This is to prevent alloimmunisation to the RhD antigen and ultimately prevent haemolytic disease of the fetus and newborn (HDFN) in future pregnancies should she survive. RhD-negative blood products are scarce in both military and civilian blood stocks.

View Article and Find Full Text PDF

Alloimmunization during pregnancy occurs when a mother produces antibodies against fetal antigens, leading to complications like hemolytic disease of the fetus and newborn (HDFN) and fetal and neonatal alloimmune thrombocytopenia (FNAIT). HDFN involves destruction of fetal red blood cells, potentially causing severe anemia, hydrops fetalis, and fetal death. FNAIT affects fetal platelets and possibly endothelial cells, resulting in risk of intracranial hemorrhage and brain damage.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!